TRICARE's coverage policies for weight loss medications, including GLP-1 drugs like Wegovy and Zepbound
00:19:35 Narrator Even better, share what you learned with a friend or a colleague and let them know they can find the show on any podcast app or on YouTube
This is due to a variety of issues, from procurement, supply chain, and financial coverage, to the accessibility, affordability and availability of GLP-1 receptor agonists [which] remain highly inadequate to meet the population-level needs. Mind the evidence gap Despite the plethora of short-term evidence for GLP-1s in the management of weight loss, almost nothing is known about the possible long-term effects of these artificial peptide hormones
BPC-157 (Body Protection Compound-157) Research Focus: Investigated for its influence on tissue matrix dynamics, angiogenesis modulation, and gastrointestinal tract cellular stability
#ESCCongress #WCCardio #ESC75Years | JAMA